Press release
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLDSymposium™ 2023, an annual research conference dedicated to lysosomal diseases. WORLDSymposium 2023 is held February 22-26, 2023, in Orlando, Florida. Arimoclomol is an orally-delivered, first-in-class investigational product candidate being developed as a treatment for NPC, a rare neurodegenerative lysosomal disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. Arimoclomol has been studied in ten Phase 1, four Phase 2, and three pivotal Phase 2/3 trials. Zevra is currently preparing an updated New Drug Application (NDA) for arimoclomol as a treatment for NPC, which the Company expects to file as early as the third quarter of 2023. Details of the presentations are as follows: Poster Number: 277Title:Evaluation of the long-term effect of arimoclomol in NPCPoster Session:Friday, February 24, 2023, 4:00 – 5:00 PM, ETPresenter:Marc Patterson, MD, Professor of Neurology, Pediatrics, and Medical Genetics, Mayo Clinic Children's Center in Rochester, MN Poster Number: 83Title:Association between NPC severity score domains and corresponding items of the performance-based Scale for the Assessment and Rating of Ataxia (SARA)Poster Session:Saturday, February 25, 2023, 3:00 – 4:00 PM, ETPresenter:Christine í Dali, MD, Child Neurologist, Chief Medical Officer, Zevra Therapeutics (formerly KemPharm), Celebration, FL, USA Additional information regarding the WORLDSymposium presentations can be found at: https://worldsymposia.org/. Along with the new name, Zevra Therapeutics, the Company has recently adopted a new logo and launched a new corporate website. Visit www.zevra.com to learn more. About ZevraZevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, regulatory, and commercialization strategies, the Company ...